The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 260.00
Bid: 220.00
Ask: 300.00
Change: 0.00 (0.00%)
Spread: 80.00 (36.364%)
Open: 260.00
High: 260.00
Low: 260.00
Prev. Close: 260.00
SPSC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Financial Officer

23 Jan 2017 07:00

RNS Number : 7780U
Spectra Systems Corporation
23 January 2017
 

Spectra Systems Corporation

("The Company" or "Spectra Systems")

Appointment of Chief Financial Officer

Spectra Systems, a leading supplier of authentication technology for banknotes, brand authentication and tax stamps, is delighted to announce that, subject to the satisfactory conclusion of due diligence, it has agreed to appoint Brian E McLain C.P.A. (aged 41) as its new Chief Financial Officer.

Brian McLain started his career in 1997 at Arthur Andersen prior to working as a senior accountant at Excelergy Corporation, a software business, located in Lexington, MA from 2000 until 2003. Until late 2006, he then progressed through various roles at International Power, a UK owned power producer located in Marlborough MA, prior to joining SeraCare Life Sciences, Inc, a manufacturer of biological products for the diagnostics and drug discovery markets located in Milford MA. At SeraCare, which was quoted on NASDAQ prior to being bought out in 2012, he progressed from the role of Corporate Controller to Vice President, Finance & Business Solutions. In 2014, he then joined OMNIlife Science Inc., a manufacturer and distributor of orthopaedic devices located in Raynham, MA, in the role of Corporate Controller.

A further announcement will be made upon the conclusion of due diligence by certain of Spectra's customers and the completion of standard regulatory AIM background checks. This due diligence is expected to be completed by no later than February 2017. In the meantime, Doug Anderson, the previous Chief Financial Officer is continuing to assist Spectra as necessary.

Brian McLain joined SeraCare Life Sciences Inc. ("SeraCare") in January 2007, at which point it was already in a bankruptcy process. All creditors were subsequently settled and SeraCare exited the bankruptcy process. There are no other matters which are required to be announced pursuant to paragraph (g) of Schedule 2 to the AIM Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

Dr. Nabil Lawandy, CEO of Spectra Systems, stated: "I am delighted to welcome Brian to Spectra Systems and believe that his extensive financial experience in both private and public businesses as well as his experience in technology driven companies will be of immense value to us."

Enquiries:

Spectra Systems Corporation

Dr. Nabil Lawandy, Chief Executive Officer Tel: +1 (0) 401 274 4700

WH Ireland Limited

Chris Fielding (Head of Corporate Finance) Tel: +44 (0) 20 7220 1650

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEFFWSFWSEFF
Date   Source Headline
27th Mar 20247:00 amRNSAudited results for 12 months ended 31 Dec 2023
11th Jan 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
28th Dec 20237:00 amRNSExercise of Options
21st Dec 202312:15 pmRNSCompletion of Acquisition
15th Dec 20234:35 pmRNSExercise of Options and transfer of shares
4th Dec 20237:00 amRNSAcquisition of Cartor Holdings Limited
6th Nov 20234:43 pmRNSTR-1
12th Oct 20237:00 amRNSLargest Central Bank Consumables Order
25th Sep 20237:00 amRNSInterim Results for Six Months Ended 30 June 2023
7th Jul 20236:01 pmRNSRemoval of Regulation S restrictions from shares
26th Jun 20233:22 pmRNSAnnual General Meeting Lack of Quorum
30th May 20237:00 amRNSAppointment of Chief Financial Officer
25th Apr 20237:00 amRNSAdditional Sensor Services Contract Amendment
24th Apr 20237:00 amRNSResignation of Chief Financial Officer
19th Apr 20237:05 amRNSRemoval of Reg S restrictions from common stock
6th Apr 20237:00 amRNSExercise of Options
31st Mar 20235:14 pmRNSRemoval of Reg S restrictions from shares
21st Mar 202311:44 amRNSDividend Record Date
20th Mar 20237:00 amRNSAudited results for year ended 31 December 2022
16th Mar 20234:35 pmRNSExercise of Options
6th Mar 202310:39 amRNSRemoval of Reg S restrictions from common stock
11th Oct 20226:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSContract Amendment to a Central Bank
21st Sep 20227:00 amRNSExercise of Options
12th Sep 20227:05 amRNSAppointment of Non-Executive Director
12th Sep 20227:00 amRNSInterim Results for Six Months Ended 30 June 2022
16th Aug 20227:00 amRNSFirst Banknote Disinfection System Sold
15th Aug 20227:00 amRNSNew Central Bank Contract Amendment
28th Jul 20227:00 amRNSShare Buy-Back
1st Jul 20222:31 pmRNSShare Buy-Back
28th Jun 20227:00 amRNSShare Buy-Back
15th Jun 20227:00 amRNSAdditional Central Bank Development Revenues
14th Jun 20227:00 amRNSAppointment of Chief Financial Officer
13th Jun 20227:00 amRNSAnnual General Meeting Update
25th May 20227:00 amRNSExercise of Options and Director/PDMR Shareholding
20th May 20228:44 amRNSRemoval of Regulation S restrictions from shares
20th May 20228:41 amRNSResignation of Chief Financial Officer
3rd May 20227:00 amRNSPosting of Annual Report & Notice of AGM
6th Apr 20221:36 pmRNSRemoval of Reg S restrictions from common stock
28th Mar 20227:00 amRNSGrant of Share Options
21st Mar 20227:00 amRNSResults twelve months ended 31 December 2021
24th Jan 20227:00 amRNSNew contract awards
21st Jan 20227:00 amRNSExercise of Options
6th Dec 20217:00 amRNSNew K-cup Orders in Q4 Exceed Expectations
2nd Nov 20213:37 pmRNSExercise of Options
25th Oct 20214:18 pmRNSRemoval of Regulation S restrictions
11th Oct 20217:00 amRNSLarge Central Bank Order
13th Sep 202110:27 amRNSHolding(s) in Company
25th Aug 202111:23 amRNSRemoval of Regulation S restrictions
21st Jul 20217:00 amRNSBanknote cleaning system also deactivates Covid-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.